[Form 4] Zymeworks Inc. Insider Trading Activity

Rhea-AI Filing Summary

Robert E. Landry, a director of Zymeworks Inc. (ZYME), was granted stock options on 08/11/2025. The award consists of options to purchase 62,000 shares of common stock at an exercise price of $12.44 per share, with an expiration date of 08/10/2035. The options vest in 36 equal monthly installments beginning one month after the grant date. Following the reported transaction, Mr. Landry directly beneficially owns 62,000 option units.

Insights

Corporate Governance Expert

TL;DR: Routine director equity award; aligns director incentives but is standard compensation practice.

The Form 4 reports a director-level option grant of 62,000 stock options at a $12.44 strike price, expiring on 08/10/2035. Vesting is explicitly stated as 36 equal monthly installments starting one month after grant, which is a common time-based vesting schedule for retention purposes. The filing shows direct beneficial ownership of the granted options. Because this is a standard compensation disclosure without other material governance events disclosed, it should be treated as a routine insider grant rather than a governance red flag.

Equity Compensation Analyst

TL;DR: Material terms disclosed; no extraordinary dilution details provided.

The report provides clear compensation terms: 62,000 options, $12.44 exercise price, and a 36-month monthly vesting schedule starting one month after grant. The expiration date of 08/10/2035 gives a roughly 10-year contractual life. The Form 4 indicates the award was acquired (transaction code A) and is held directly. The filing lacks additional context such as total outstanding shares or aggregate dilution impact, so the disclosure is complete for the grant but limited in assessing company-level dilution from this single grant.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Landry Robert E

(Last) (First) (Middle)

C/O ZYMEWORKS INC.

108 PATRIOT DRIVE, SUITE A

(Street)

MIDDLETOWN DE 19709

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Zymeworks Inc. [ ZYME ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$12.44	08/11/2025		A		62,000		(1)	08/10/2035	Common Stock	62,000	$0.00	62,000	D

Explanation of Responses:

1. Stock options vest in 36 equal monthly installments starting one month after grant date of August 11, 2025.

	/s/ Daniel Dex, Attorney-in-Fact	08/12/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Zymeworks (ZYME) report in the Form 4 for Robert E. Landry?

The Form 4 reports a grant of 62,000 stock options to director Robert E. Landry on 08/11/2025.

What are the exercise price and expiration date for the options granted to Robert E. Landry (ZYME)?

The options have an exercise price of $12.44 per share and an expiration date of 08/10/2035.

How do the options awarded to ZYME director Robert E. Landry vest?

The options vest in 36 equal monthly installments, starting one month after the grant date (grant date listed as 08/11/2025).

How many derivative securities does Robert E. Landry beneficially own after the reported transaction?

Following the transaction, Mr. Landry is shown as directly beneficially owning 62,000 option units.

Was the reported transaction an acquisition or disposition for ZYME director Robert E. Landry?

The filing indicates the transaction code is "A", meaning the derivative securities were acquired.